Cart
sales@molnova.com
Heliotrine N-oxide
CAS No. 6209-65-0
Heliotrine N-oxide( —— )
Catalog No. M31048 CAS No. 6209-65-0
Heliotrine N-oxide is the pyrrolizidine alkaloid (PA) N-oxide counterpart of Heliotrine. It induces the generation of pyrrolic DNA adducts, potentially initiating PA-induced liver tumors in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameHeliotrine N-oxide
-
NoteResearch use only, not for human use.
-
Brief DescriptionHeliotrine N-oxide is the pyrrolizidine alkaloid (PA) N-oxide counterpart of Heliotrine. It induces the generation of pyrrolic DNA adducts, potentially initiating PA-induced liver tumors in vivo.
-
DescriptionHeliotrine N-oxide is the pyrrolizidine alkaloid (PA) N-oxide counterpart of Heliotrine. It induces the generation of pyrrolic DNA adducts, potentially initiating PA-induced liver tumors in vivo.
-
In VitroDNA adduct is a segment of DNA bound to a cancer-causing chemical. This process could be the start of a cancerous cell, or carcinogenesis.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number6209-65-0
-
Formula Weight329.39
-
Molecular FormulaC16H27NO6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
TAT 14
TAT 14, a 14-mer peptide, is an Nrf2 activator with anti-inflammatory properties. TAT-14 increases Nrf2 protein levels due to targeting the Nrf2 binding site on Keap1, but has no effect on Nrf2 mRNA expression.
-
Neobavaisoflavone
Neobavaisoflavone is isolated as a DNA polymerase inhibitor.
-
TGFβ1-IN-2
TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research .
